RxDoctor Payments Data

Stephanie Jacobs, MD

Obstetrics & Gynecology · Baltimore, MDNPI 1699093666

Payments from drug & device makers

$4,190in general payments, 2019–2025

Across 123 payments — averaging $34.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Astellas Pharma US Inc$542
  • Sumitomo Pharma America, Inc.$371
  • Boston Scientific$228
  • AbbVie$179
  • Myovant Sciences Inc.$117
  • plus $590 from 13 others

What the payments were for

  • Travel & lodging$1,03025%
  • Food & beverage$2,73365%
  • Education$42810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,190 in reported general payments places this provider in the 85th percentile of 842 obstetrics & gynecology providers in Maryland.

See all obstetrics & gynecology providers in Maryland

Medicare billing

Part B allowed, 2024
$298,900
Medicare patients
508
Services billed
11,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron283$180,596
MyrbetriqMirabegron189$156,533
Estradiol229$17,605
PremarinEstrogens, Conjugated27$11,405
Mirabegron ErMirabegron12$9,857
Methenamine Hippurate94$5,370
Trospium Chloride ErTrospium Chloride15$4,580
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst228$2,163
Trospium Chloride37$1,337
Solifenacin Succinate28$1,017
Clobetasol Propionate18$544
Oxybutynin Chloride ErOxybutynin Chloride30$448
Cefdinir44$418
Fluconazole50$245
Ciprofloxacin Hcl31$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$371$180,596283 claims
Astellas Pharma US IncMyrbetriq$542$156,533189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 842 obstetrics & gynecology providers in Maryland.

Other obstetrics & gynecology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →